Introduction {#Sec1}
============

The incidence of urinary stone disease among the paediatric population is rising \[[@CR1]\]. This has led to the development of minimally invasive and effective endourological interventions that can yield a high stone clearance whilst preserving renal function with low morbidity in these children. In the adult population, application of ureteroscopy (URS) globally has expanded over 200% in the past decade \[[@CR2]•\]. This shift owes largely to major advances in surgical technique, laser technology and equipment minimisation. Similar changes have been mirrored in the management of paediatric stone disease, although Ritchey et al. first described URS in a young child in 1988 \[[@CR3]\]. Whilst there has been a rise in the number of original studies published on this topic, critical evaluation of the safety and efficacy of URS for paediatric cases remains under-reported. The objective of this study was to therefore formally appraise the existing evidence. Furthermore, given the dissemination of URS and that its uptake is no longer limited to specialist centres, we sought to determine if there were any differences in clinical outcomes among these high-volume centres compared to those reporting medium volumes.

Material and Methods {#Sec2}
====================

Evidence Acquisition: Criteria for Considering Studies for This Review {#Sec3}
----------------------------------------------------------------------

### Inclusion Criteria {#Sec4}

Studies reporting on outcomes following ureteroscopy in paediatric populationsPatients aged ≤ 18

### Exclusion Criteria {#Sec5}

Study sample size \< 25 patientsNon-English language articlesAnimal studies

Search Strategy and Study Selection {#Sec6}
-----------------------------------

A Cochrane style search was performed to identify all original articles investigating ureteroscopy in paediatric patients (Fig. [1](#Fig1){ref-type="fig"}). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was adhered to accordingly. Sensitive and customised search strategies were applied to the following online bibliographic databases: PubMed/MEDLINE, EMBASE, CINAHL and The Cochrane Central Register of Controlled Trials, whilst citation lists and study references were also evaluated.Fig. 1PRISMA flow chart of the current literature

Search terms included (but not limited to) 'ureteroscopy', 'URS', 'retrograde intra-renal surgery', 'RIRS', 'paediatric', 'pediatric', 'urolithiasis' and 'stones'. Boolean operators (AND, OR) were incorporated to refine the search. Medical subject headings (MeSH) included (not limited to) \[Urinary calculi\], \[Ureteroscopy\], \[Lasers\], \[Child\] and \[Nephrolithiasis\].

All study types were considered for potential inclusion. A time restriction was applied to include relevant studies published between January 1990 and December 2016. Paediatric age was defined as 18 years or less. Studies combining adult and paediatric populations with no breakdown of results were excluded.

Outcomes of Interest {#Sec7}
--------------------

### Primary Outcomes {#Sec8}

Procedure-related complications (graded according to Clavien-Dindo system)Stone-free rates (SFRs)

### Secondary Outcomes {#Sec9}

Comparison of outcomes for ureteroscopy performed in medium-volume centres (reporting 25--49 procedures) and high-volume centres (reporting ≥ 50 procedures).

Data Extraction and Analysis {#Sec10}
============================

Both the search process and data extraction were performed by two authors (SR, PJ) independently and overseen by the senior author (BKS). Information was also collected on patient characteristics, total number of procedures performed and stone location. For the purposes of this review, centres reporting on 25--49 procedures were termed 'medium-volume' and ≥ 50 procedures as 'high-volume' centres. We did not include studies from centres that reported on \< 25 procedures, which were deemed to be low-volume centres. Complications recorded intra-operatively or within the study follow period were included for analysis.

Chi-squared test and independent *t* test were used for dichotomous and continuous data respectively (SPSS version 21).

Results {#Sec11}
=======

Thirty-four studies \[[@CR4]--[@CR24], [@CR25]•, [@CR26]--[@CR32], [@CR33]••, [@CR34]--[@CR37]\] satisfied our search criteria and were included in this review (Table [1](#Tab1){ref-type="table"}). These were all published between 1996 and 2016. A total of 2758 children underwent URS for urinary stone disease. The mean age was 7.8 years (range 0.25--18) with a male to female ratio of 1:1. No significant difference in age was present between these groups (*p* \> 0.05). The mean stone size was 8.6 mm (range 1--30). Breakdown by stone location was as follows: upper ureter 13.3%, mid ureter 12.5%, lower ureter 56.6%, renal pelvis 3.5%, upper pole 1.2%, mid pole 1%, lower pole 8.4%, other 3.5%.Table 1Demographics of patients reported in the studiesAuthorJournalYearCountryNo. of proceduresSample size (male/female)Mean age (years) (range)Mean stone size (range) (mm)Medium-volume centres Schuster \[[@CR6]\]Journal of Urology2002USA27\*25 (13/12)9.2 (3 to 14)6 (2--12) Dogan \[[@CR7]\]BJU International2004Turkey35\*35 (15/20)6.2 (1 to 14)8 (4--15) Satar \[[@CR8]\]Journal of Urology2004Turkey33\*33 (NR)7.4 (0.75 to 15)5.3 (3--10) Al-Busaidy \[[@CR9]\]BJU International2004Oman28\*26 (14/12)6.5 (2--12)12.1 (4--22) Thomas \[[@CR12]\]J Urol2005USA33\*29 (15/14)7.8 (0.4--12)6 (3--9) El-assmy \[[@CR13]\]Journal of Endourology2006Egypt33\*32 (NR)8.7 (2--15)7 (4--15) Ertuhan \[[@CR16]\]Journal of Endourology2007Turkey41\*41 (16/25)9.5 (3--15)5.6 (4--10) Corcoran \[[@CR17]\]J Urol2008USA30\*309.7 (2.2--14.4)8.8 (1.5--25) Yeow \[[@CR20]\]J Indian Assoc Pediatr Surg2009Australia26\*26 (14/12)8.2 (0.25--15)10.3 (3--21) Chedgy \[[@CR31]\]Urologia Internationalis2015UK32\*21 (13/8)8.6 (1.4--16)9.6 (5--20) Featherstone \[[@CR33]••\]Journal of Paediatric urology2016UK35\*18 (7/11)10.4 (3.6--15)13.2 (10--25) Iqbal \[[@CR35]\]Urology2016Pakistan37\*37 (25/12)8.37 (NR)10.01 (NR) Utangac \[[@CR36]\]JCPSP2016Turkey34\*34 (22/12)0.8 (0.33--12)NRHigh-volume centres Al Busaidy \[[@CR4]\]British Journal of Urology1997Oman50\*\*43 (29/14)6.2 (0.5--12)12.6 (4--22) Bassiri \[[@CR5]\]Journal of Endourology2002Iran66\*\*66 (NR)9 (2--15)8 (5--15) Minevich \[[@CR10]\]Journal of Urology2005USA81\*\*71 (39/32)7.5 (1--12)NR Raza \[[@CR11]\]Journal of Endourology2005UK52\*\*35 (25/10)5.9 (0.9--15)8.8 (3--20) Gedik \[[@CR14]\]International Urology and Nephrology2007Turkey54\*\*54 (32/22)8.5 (1--16)7.1 (4--12) Smaldone \[[@CR15]\]Journal of Urology2007USA115\*\*100 (42/58)13.28.3 Tanaka \[[@CR18]\]Journal of Urology2008USA52\*\*50 (31/19)7.9 (1.2--13.6)8 (1--16) Kim \[[@CR19]\]Journal of Urology2008USA170\*\*167 (89/78)5.2 (0.25--18)NR Tanriverdi \[[@CR21]\]Paediatric Surgery International2010Turkey65\*\*65 (39/26)9.1 (2--16)6.1 (3--24) Turunc \[[@CR22]\]Journal of Endourology2010Turkey66\*\*61 (NR)8.1 (0.5--16)9.5 (3--30) Ghazaleh \[[@CR23]\]Saudi Journal of Kidney Diseases and Transplantation2011Jordan78\*\*56 (38/18)8.2 (6--14)8.2 (4--20) Nerli \[[@CR24]\]Journal of Endourology2011India88\*\*80 (69/11)9.5 (6--12)12 (9--15) Dogan \[[@CR25]•\]Journal of Urology2011Turkey660\*\*642 (265/377)7.5 (0.33--17)10.2 (7--16) Yucel \[[@CR26]\]World journal of urology2011Turkey54\*\*48 (28/20)7.6 (0.75--18)8.9 (NR) Atar \[[@CR27]\]Urological research2012Turkey69\*\*64 (23/41)4.3 (NR)NR Resorlu \[[@CR28]\]Urology2012Turkey95\*\*95 (53/42)9.3 (1--17)14.3 (NR) Jurkiewicz \[[@CR29]\]Urolithiasis2013Germany157\*\*126 (66/60)7.5 (0.8--17)7.2 Ezkurt \[[@CR30]\]Urolithiasis2013Turkey65\*\*65 (31/34)4.3 (0.5--7)14.66 (7--30) Sen \[[@CR32]\]Journal of Paediatric urology2015Turkey175\*\*175 (101/74)4 (NR)9.6 (5--20) Gokce \[[@CR34]\]Urology2016Turkey116\*\*116 (78/38)9.5 (NR)9.4 (NR)Other Guven \[[@CR37]\]Urology2016^a^Global (over 23 countries)192192 (109/83)10.3 (NR)4.56 (1.96--9.43)^\*^Medium volume centre; ^\*\*^High volume centre^a^Multicentric study

Overall, 2944 procedures were performed with a mean caseload of 87 procedures per study (range 25--660). There were 13 and 20 studies in the medium-volume \[[@CR6]--[@CR9], [@CR12], [@CR13], [@CR16], [@CR17], [@CR20], [@CR31], [@CR33]••, [@CR35], [@CR36]\] and high-volume \[[@CR4], [@CR5], [@CR10], [@CR11], [@CR14], [@CR15], [@CR18], [@CR19], [@CR21]--[@CR24], [@CR25]•, [@CR26]--[@CR30], [@CR32], [@CR34]\] groups respectively. Given the paediatric data from the CROES database that was gathered from over 50 centres, it was excluded from this subclassification although the data was used for the overall results \[[@CR37]\].

Outcome Measures {#Sec12}
================

All studies reported SFR, with an overall SFR of 90.4% (range 58--100). Medium-volume centres reported a mean SFR of 94.1% (range 87.5--100). High-volume centres reported a mean SFR of 88.1% (range 58--98.5). Mean number of sessions to achieve stone-free status in medium-volume and high-volume groups was 1.1 and 1.2 procedures/patient respectively (Table [2](#Tab2){ref-type="table"}).Table 2Results of the studies (stone location, SFR, failure to access and complications)AuthorStone location (*n*)SFR (%)Failures (*n*)Complications (*n*)Upper ureterMid ureterLower ureterRenal pelvisUpper poleMid poleLower poleOther stonesMedium-volume centres Schuster \[[@CR6]\]NRNRNRNRNRNRNRNR1000Stent migration (1), pyelonephritis (1) Dogan \[[@CR7]\]2--33----------971Ureteric perforation (2) Satar \[[@CR8]\]6326----------942UTI (1) Al-Busaidy \[[@CR9]\]6517----------922Transient haematuria (4), fever (2) Thomas \[[@CR12]\]35241--------961/33Extravasation (1) El-Assmy \[[@CR13]\]2229----------96.91/33Extravasation (1), transient haematuria (1) Erturhan \[[@CR16]\]41527--------87.75/41Nil Corcoran \[[@CR17]\]NRNRNRNRNRNRNRNR942/30Ureteral perforation (2), urinoma (1) Yeow \[[@CR20]\]NRNRNRNRNRNRNRNR88.53/26Nil Chedgy \[[@CR31]\]NRNRNRNRNRNRNRNR950UTI (1) Featherstone \[[@CR33]••\]2--5473214891Nil Iqbal \[[@CR35]\]NRNRNRNRNRNRNRNR1000Pyelonephritis (2), haematuria (4) Utangac \[[@CR36]\]492----------94.10Minimal bleeding (2), ureteral perforation (1), UTI (2)High-volume centres Al Busaidy \[[@CR4]\]9734----------933/43Ureteric perforation (2) Bassiri \[[@CR5]\]2559----------883/66Transient haematuria (11), pyelonephritis (3), renal colic (1) Minevich \[[@CR10]\]1614287--------980Nil Raza \[[@CR11]\]0372--------287.20Ureteric perforation (2), urinary retention (1), mild fever (5), mucosal tear (1) Gedik \[[@CR14]\]31625----------77.82Pyrexia (3) Smaldone \[[@CR15]\]191137610--17--910Ureteric perforation/extravasation (5), ureteral stricture (1) Tanaka \[[@CR18]\]------27----1311580Re-admission due to nausea and vomiting (1) Kim \[[@CR19]\]--4719------871498.50Nil Tanriverdi \[[@CR21]\]5233----------89.22Mucosal lacerations (2), minor haematuria (1) Turunc \[[@CR22]\]7950----------92.45Pyrexia (1) Ghazaleh \[[@CR23]\]------3464--2494.80UTI (3), haematuria (1) Nerli \[[@CR24]\]56------------2497.52Intra-operative bleeding (6), self-limiting post-operative bleeding (8), pyrexia (4) Dogan \[[@CR25]•\]9673480--------21909/660Stone migration (8), mucosal laceration (1), broken catheter (1), ureteral perforations (5), haematuria (2) (1 intra-op, 1 post-op), post-op pain (2), febrile UTI (20), urinary retention (1), 1 urethral stone (1), late ureterovesical junction obstruction (4) Yucel \[[@CR26]\]NRNRNRNRNRNRNRNR84.38/54Ureteral perforation (3), urosepsis (30), ureteral obstruction with stone fragment (1) Atar \[[@CR27]\]6954----------85.612Mild haematuria (8), ureteral laceration (8), ureteric perforation (4), urinoma (1), renal colic (5), febrile UTI (9), urinary retention (7), bleeding/false route/perforation intra-operatively (5) Resorlu \[[@CR28]\]NRNRNRNRNRNRNRNR92.60Minor complications (Clavien I/II) 8.4%\
Major complications (Clavien III--V) nil Jurkiewicz \[[@CR29]\]NRNRNRNRNRNRNRNR98.14/15Ureteral perforation (1), ureterovesical stenosis (1) Ezkurt \[[@CR30]\]------22101228--92.35/65Pyelonephritis (10), haematuria (6), ureteral wall injury (2) Sen \[[@CR32]\]NRNRNRNRNRNRNRNR66NRFever (30), ureteral laceration (8), sepsis (6) Featherstone \[[@CR33]••\]2--5473214891Nil Gokce \[[@CR34]\]NRNRNRNRNRNRNRNR873/116Mucosal injury (8), renal colic (22)Other Guven \[[@CR37]\]NRNRNRNRNRNRNRNR89.2NRPain (1), stricture (2)*NR* not reported

Across all the included studies, the overall complication rate was 11.1% (327/2994). Breakdown by Clavien grade was as follows: Clavien I 69% and Clavien II/III 31% (Table [3](#Tab3){ref-type="table"}). There were no Clavien IV/V complications, and no mortality was recorded across any of the studies.Table 3Complications reported in studies from medium-volume and high-volume centresNature of complicationClavien gradeNumber of complications (*n*)Medium volumeHigh volumePost-operative renal colicI--2HaematuriaI936UTI/pyelonephritisI472Mild fever/pyrexia post-operativelyI1234Urinary retentionI18Post-operative renal colicI--29Re-admission due to nausea and vomitingI--1Urethral stoneI--1Late ureterovesical junction obstructionIII--5Stent migrationIII18Ureteral stricturesIII--1Post-operative ureteral stoneIII----Broken catheterIII--1Intra-operative bleeding/false passage/ureteral perforation/tear/laceration/submucosal wireIII1063Stone migrationIII--8Total--37269

Medium-volume and high-volume studies had overall complication rates of 6.9% (37/530) and 12.1% (287/2222) respectively. There was no significant difference in major or minor complications between these two groups. The overall failure rate was 2.5% (76/2944). Most of them were due to failure to access the paediatric ureter.

Discussion {#Sec13}
==========

Findings and Implications of Our Review {#Sec14}
---------------------------------------

This is the largest review on paediatric URS to date and reveals an overall SFR of 90.4% and an overall complication rate of 11.1%. Over two thirds of these complications were Clavien I. Importantly, there was no significant difference in SFR or complication rates between medium-volume and high-volume centres.

PCNL in Paediatric Population {#Sec15}
-----------------------------

Percutaneous nephrolithomy (PCNL) and shockwave lithotripsy (SWL) represent the key alternative interventions to URS. Whilst the former can achieve high stone-free rates in a single procedure and is not limited by failure to access the ureter such as can occur in URS, it carries a worse morbidity profile, notably in the form of haemorrhagic complications. Bhageria et al. reported transfusion rate of 9% in their retrospective cohort of 95 children undergoing PCNL \[[@CR38]\]. Miniaturisation of standard equipment (\< 24Fr) has delivered a key strategy for improving its safety status both in adult and paediatric populations. Multiple studies have confirmed higher incidence of haematuria and renal extravasation associated with the use of larger tract sizes \[[@CR39]\]. PCNL can now even be delivered in the 'micro' format using a 4.5Fr tract with final SFRs reported between 80 and 100% \[[@CR39]\]. Its use for treatment of ureteric stones however remains less valuable \[[@CR40]\].

SWL in Paediatric Population {#Sec16}
----------------------------

Shockwave wave lithotripsy is a minimally invasive option, with a relatively short learning curve and generally minor complications \[[@CR40]\]. It has traditionally been the first-line intervention for paediatric stone disease. However, it can necessitate multiple sittings and in children generally requires administration of general anaesthetic. Additionally, SFRs are less predictable with stone recurrences commonly due to incomplete stone clearances \[[@CR41]\].

Future Trends in Ureteroscopy {#Sec17}
-----------------------------

With increased uptake of URS, it looks set to reach an increasing number of endourological milestones. URS has also undergone the miniaturisation process. Utangac et al. recently reported using a micro-ureteroscope (4.5Fr along entire length) in 11 children with a median stone size of 10.5 mm \[[@CR41]\]. Stone-free status was achieved in all cases. There were no intra-operative complications and only one case of transient haematuria post-operatively. This novel modification may prove extremely valuable and allow better ureteric cannulation/navigation with fewer cases of access failure. However, further studies are needed comparing it with standard URS.

Limitations of Our Study {#Sec18}
========================

Whilst this study represents the largest review to date on paediatric URS, there are certain limitations, which the authors acknowledge. Results have been included from predominantly retrospective studies with age ranges spanning development of the urinary tract from infancy to adult state. The heterogeneity of available evidence did not allow for formal meta-analysis to be performed. In comparison, we did find a relatively higher stone-free rate with lower complications in medium-volume centres. However, we feel that this might reflect higher complexity of cases in established endourology high-volume centres. Similarly, training and guidance on 'tips and tricks' of ureteroscopy might help improve outcomes in less well-established paediatric stone centres \[[@CR42], [@CR43]\].

Conclusion {#Sec19}
==========

URS is a safe and effective treatment for the treatment of stone disease among the paediatric population. Medium-volume centres can achieve equally high SFRs and safety profiles as high-volume centres. The findings of this review may therefore support increased uptake of URS in centres performing fewer procedures each year.
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